Text Size:

Who should not get meningococcal vaccine?


who should not get

Contraindications to receiving Menactra meningococcal (Groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine documented in Sanofi Pasteur’s product insert include:1

  • Individuals who experienced a severe allergic reaction after a previous dose of a meningococcal capsular polysaccharide, diphtheria toxoid, or CRM197- containing vaccine, or to any ingredient found in Menactra vaccine.

Menactra vaccine product insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with Menactra vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination.

There are no well-controlled or adequate studies on the use of Menactra vaccine in pregnant women and no available data on the impact of Menactra vaccine on breastfeeding infants or on human milk excretion and production.

Menactra vaccine is approved for use in adults and children age of 9 months through 55 years of age. Menactra vaccine is not approved for use in infants younger than 9 months of age or in adults older than 55 years of age.

Contraindications to receiving Menveo meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) product insert include:2

  • Individuals who experienced a severe allergic reaction after a previous dose of Menveo, any component of the vaccine, or any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.

Menveo vaccine product insert also warns that persons with a previous medical history of Guillain-Barre Syndrome (GBS) may be at an increased risk of the disease following administration with the vaccine. The decision to vaccinate should be made only after careful consideration of the potential risks and possible benefits to vaccination.

Infants born prematurely are considered to be at a greater risk for apnea following intramuscular vaccination. The Menveo meningococcal vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination.

Menveo vaccine is a Pregnancy Category B product and there are no well controlled or adequate studies on the use of Menveo in pregnant or lactating women. The product insert warns that Menveo should only be used in pregnant women if absolutely necessary.

Menveo vaccine is approved for use in persons 2 months through 55 years of age. Menveo vaccine is not approved for use in infants younger than 2 months of age or in adults older than 55 years of age.

Contraindications to receiving BEXSERO meningococcal group B vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) product insert include:3

  • Individuals who experienced hypersensitivity or a severe allergic reaction after a previous dose of BEXSERO or to any ingredient found in the vaccine.

Persons with a latex sensitivity may be at greater risk for an allergic reaction if they receive a dose of BEXSERO from prefilled syringes as the tip caps of prefilled syringes contain natural rubber latex.

BEXSERO is a Pregnancy Category B product and there are no well-controlled or adequate studies on the use of BEXSERO in pregnant or lactating women. The product insert warns that BEXSERO should only be used in pregnant women if absolutely necessary and caution is advised when administering the vaccine to nursing mothers.

BEXSERO vaccine is approved for use in persons 10 through 25 years of age. BEXSERO vaccine is not approved for use in children younger than aged 10 or in adults older than 25 years.

Contraindications to receiving TRUMENBA meningococcal group B vaccine documented in Wyeth Pharmaceutical (Pfizer) product insert include:4

  • A severe allergic reaction after a previous dose of TRUMENBA.

There are no well-controlled or adequate studies on the use of TRUMENBA in pregnant women and no available data on the impact of TRUMENBA vaccine on breastfeeding infants or on human milk excretion and production.

TRUMENBA vaccine is approved for use in persons 10 through 25 years of age. TRUMENBA vaccine is not approved for use in children younger than 10 years or in adults older than 25 years. The safety and effectiveness of TRUMENBA has not been evaluated in children under the age of 10 or in adults over the age of 65.

NVIC “Quick Facts” is not a substitute for becoming fully informed about Meningococcal disease, meningitis and the Meningococcal vaccine. NVIC recommends consumers read the more complete information following the "Quick Facts", as well as the vaccine manufacturer product information inserts, and speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child.

« Return to Vaccines & Diseases Table of Contents

References

1 FDA Menactra Product Insert Apr. 27, 2018

2 FDA Menveo Product Insert Oct. 4, 2018

3 FDA BEXSERO Product Insert May 31, 2018

4 FDA TRUMENBA Product Insert Mar. 14, 2018


Make a Difference Support NVIC

NVIC is 100% funded by donations.
Please give.

Help educate families about preventing vaccine injury and death by donating to NVIC today.

Discover How You Can Take Action to Support Our Efforts

Support NVIC!


Connect with us!

  • NVIC Pinterest
  • NVIC Facebook
  • NVIC Twitter
  • NVIC Youtube
  • NVIC Instagram

Ask 8 Kiosk & Educational Marketplace

Ask 8 Questions

Visit our Ask 8 Kiosk to explore a variety of FREE educational materials, from posters and brochures to embeddable web graphics and other resources.

View FREE Downloads